
What We’re Reading: Omicron Booster Delayed; AstraZeneca Discount Program Lawsuit; Airline Masks Mandates Challenged
Pfizer and BioNTech’s Omicron vaccine development has been delayed; a US judge said HHS violated procedural rules in a dispute with AstraZeneca over the 340B drug discount program; Texas filed suit against the CDC’s mask mandate for airline passengers.
Pfizer/BioNTech Omicron Booster Is Delayed
Pfizer/BioNTech’s Omicron booster dose of its COVID-19 vaccine was delayed several weeks because of a slower-than-expected data gathering process, according to a report from
AstraZeneca Suit Over 340B Can Proceed
A US judge ruled Wednesday that HHS, which threatened AstraZeneca with penalties, was incorrect in telling the company to resume providing discounts through the 340B drug discount program, which primarily serves low-income patients. The 340B program requires drug developers to offer discounts on all outpatient drugs to hospitals and other safety-net facilities. The discounts are typically estimated to be 25% to 50% but could be more.
Texas Sues CDC Over Mask Mandates on Airlines
The state of Texas is suing over the CDC’s mask mandate for passengers on airlines, saying that the agency lacks the authority to implement such a blanket provision for the country and that the rule is not backed by science, according the
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.